IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 99,423-S)

In the Application of: Zablocki et al.) Examiner: Lawrence E. Crane Serial No. 10/018,446) Group Art Unit 1623

Filed: 04/12/2002)

Title: N-Pyrazole A_{2A} Receptor Agonists)

Assistant Commissioner of Patents

Washington, D.C. 20231

RESPONSE TO OFFICIAL ACTION OF AUGUST 27, 2002

Dear Sir,

This reply is responsive to the Official Action dated August 27, 2002 (Paper No. 6). Claims 1 to 25 were pending in the Application at the time of this official action. Applicants traverse the rejections presented by the Examiner and present the following arguments and amendments. Applicants reserve the right to file continuing applications directed to subject matter cancelled from this application. A three month-extension of time is enclosed with this response. A supplemental IDS is also enclosed with this response.

IN THE SPECIFICATION

On page 25, please amend the compound name on lines 4 and 5 from

(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-

yl}pyrazol-4-yl)-N-(cyclopentylmethyl)carboxamide (21)

to

(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-(cyclopentyl)carboxamide (21)

os de

A